Novartis Pharma AG: Novartis Entresto receives positive CHMP opinion for pediatric heart failure
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to Pediatric heart failure is an important cause